Biotech
Obsidian Therapeutics
Obsidian Therapeutics raises $160.5M Series C at $750M valuation
$160.5M
Total Raised
Series C
Latest Round
2014
Founded
100+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$750M
Latest Round Size
$160.5M
Latest Round Date
April 2024
Obsidian Therapeutics: Series C Funding Round
Obsidian Therapeutics has successfully raised $160.5M in Series C funding, reaching a valuation of $750M.
Company Overview
Clinical-stage biotech developing cell and gene therapies for cancer
Funding Details
The Series C round was led by New Enterprise Associates, with participation from Vida Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2014
- Employees: 100+
- Category: Biotech
Investment
Obsidian Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series C
- Vida Ventures: Verified investor in Series C
Key Investors
New Enterprise Associates
Lead Investor
Verified investor in Series C
Vida Ventures
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M